Last reviewed · How we verify

azelastine hydrochloride 0.05%

Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona · FDA-approved active Small molecule

Azelastine hydrochloride is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in the nasal mucosa.

Azelastine hydrochloride is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in the nasal mucosa. Used for Allergic rhinitis (seasonal and perennial), Vasomotor rhinitis.

At a glance

Generic nameazelastine hydrochloride 0.05%
SponsorAzienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona
Drug classH1-receptor antagonist (second-generation antihistamine)
TargetH1 receptor
ModalitySmall molecule
Therapeutic areaAllergy/Immunology
PhaseFDA-approved

Mechanism of action

Azelastine is a second-generation antihistamine that selectively antagonizes H1 receptors on mast cells and other immune cells in nasal tissue, preventing histamine release and reducing allergic inflammation. It also has anti-inflammatory properties independent of H1 blockade. The 0.05% nasal spray formulation delivers the drug topically to provide rapid relief of allergic rhinitis symptoms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: